NASDAQ:OVID - Ovid Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.95 -0.01 (-0.51 %)
(As of 04/24/2019 04:00 PM ET)
Previous Close$1.96
Today's Range$1.88 - $1.98
52-Week Range$1.66 - $11.45
Volume411,700 shs
Average Volume310,251 shs
Market Capitalization$75.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.57 per share

Profitability

Net Income$-51,980,000.00

Miscellaneous

Employees55
Market Cap$75.36 million
Next Earnings Date5/14/2019 (Estimated)
OptionableNot Optionable

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc (NASDAQ:OVID) released its earnings results on Thursday, March, 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.03. View Ovid Therapeutics' Earnings History.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Ovid Therapeutics.

What price target have analysts set for OVID?

4 brokerages have issued 1 year target prices for Ovid Therapeutics' shares. Their forecasts range from $10.00 to $27.00. On average, they expect Ovid Therapeutics' share price to reach $15.50 in the next twelve months. This suggests a possible upside of 694.9% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

What is the consensus analysts' recommendation for Ovid Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

Has Ovid Therapeutics been receiving favorable news coverage?

Media coverage about OVID stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ovid Therapeutics earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the folowing people:
  • Dr. Jeremy Max Levin, Chairman & CEO (Age 66)
  • Dr. Matthew J. During, Founder, Chairman of Scientific Advisory Board & Director (Age 62)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR
  • Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Thomas Michael Perone, Sr. VP, Gen. Counsel & Sec.

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $1.95.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $75.36 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is http://www.ovidrx.com.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]


MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  176 (Vote Underperform)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel